Back to search results
NCT06940752

VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters

Enrolling by Invitation
NAAges 21+InterventionalDevice feasibility
National Heart, Lung, and Blood Institute (NHLBI)
~30 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
VT COHORT: Freedom from appropriate implanted cardioverter-defibrillator (ICD) shocks or hospital admission due to recurrent VT
Measured over 6 months
+1 more outcome measured

Conditions

Ventricular Arrhythmia

Explore related trials

Monomorphic Ventricular Tachycardia by ECG FindingVentricular ArrhythmiaVentricular premature complex

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Robert J Lederman, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>= 21 years
Undergoing planned repeat radiofrequency catheter ablation for ventricular arrhythmias (Having failed a previous attempt at catheter ablation and at least one antiarrhythmic drug for ventricular arrhythmias)
Ventricular arrhythmia COHORT 1:
Monomorphic ventricular tachycardia
Has an implanted cardioverter defibrillator (ICD)
Hospital admission for ventricular tachycardia since most recent ablation attempt
Ventricular arrhythmia COHORT 2:
Monomorphic (unifocal), frequent, premature ventricular contraction, \>=15% burden
Either of
Symptomatic (intolerable palpitation, syncope, fatigue, dyspnea, heart failure, hospital admission for ventricular arrhythmia, appropriate ICD discharge, appropriate antitachycardia pacing), OR
Left ventricular ejection fraction \< 0.50
Willing to return for all scheduled follow-up activities, and eligible or able to undergo required protocol and testing

Exclusion

Does not consent to participate, or unable to consent to participate
Left ventricular ejection fraction \< 0.20
Hemodynamic instability or emergency procedure
Requires planned temporary mechanical circulatory device (such as percutaneous left ventricular assist device or intraaortic balloon counterpulsation pump)
Pregnant
eGFR \< 30 mL/min/1.73m\^2 or end-stage renal failure requiring renal replacement therapy
Survival despite successful procedure expected \< 6 mo

What this trial measures

  • VT COHORT: Freedom from appropriate implanted cardioverter-defibrillator (ICD) shocks or hospital admission due to recurrent VT6 months

    The primary endpoint for VT Cohort is freedom from appropriate implanted cardioverter-defibrillator (ICD) shocks or hospital admission due to recurrent VT at 6 months.

  • PVC COHORT: Reduction in PVC burden6 months

    The primary endpoint for participants treated for PVC Cohort is reduction in PVC burden at 6 months.